Lundbeck’s Lu AF35700 misses schizophrenia endpoint

The first Phase III trial from H. Lundbeck A/S (CSE:LUN) to read out since CEO Deborah Dunsire took the helm last month has missed its primary endpoint. Lundbeck slid DKK108.90 (27%) to DKK300 on Thursday when it reported that Lu AF35700 missed the primary endpoint in the Phase III DAYBREAK trial for treatment-resistant schizophrenia.